IXICO plc is a biotechnology business based in the UK. IXICO shares (IXI.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 105.5p – an increase of 2.43% over the previous week. IXICO employs 82 staff and has a trailing 12-month revenue of around £9.5 million.
Since the stock market crash in March caused by coronavirus, IXICO's share price has had significant positive movement.
Its last market close was 105.5p, which is 28.91% up on its pre-crash value of 75p and 154.22% up on the lowest point reached during the March crash when the shares fell as low as 41.5p.
If you had bought £1,000 worth of IXICO shares at the start of February 2020, those shares would have been worth £517.65 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,241.18.
|Latest market close||105.5p|
|52-week range||41.5p - 127p|
|50-day moving average||105.8309p|
|200-day moving average||86.213p|
|Wall St. target price||0.62p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||2p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-13)||16.29%|
|1 month (2020-12-23)||2.73%|
|3 months (2020-10-23)||-1.43%|
|6 months (2020-07-21)||45.77%|
|1 year (2020-01-21)||24.32%|
|2 years (2019-01-21)||364.54%|
|3 years (2018-01-19)||217.00%|
|5 years (2016-01-21)||233.87%|
Valuing IXICO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IXICO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IXICO's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, IXICO shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IXICO's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £1 million.
The EBITDA is a measure of a IXICO's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£9.5 million|
|Operating margin TTM||8.98%|
|Gross profit TTM||£6.3 million|
|Return on assets TTM||4.69%|
|Return on equity TTM||11.18%|
|Market capitalisation||£48.3 million|
TTM: trailing 12 months
We're not expecting IXICO to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
IXICO's shares were split on a 1:50 basis on 4 September 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your IXICO shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for IXICO shares which in turn could have impacted IXICO's share price.
Over the last 12 months, IXICO's shares have ranged in value from as little as 41.5p up to 127p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while IXICO's is 0.8915. This would suggest that IXICO's shares are less volatile than average (for this exchange).
IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.